Sexual Dysfunction

The aetiology and treatment of premature ejaculation
pp. 59-69(11)
Authors: Goldmeier D.; Keane F.

The treatment of erectile dysfunction with alprostadil
pp. 71-76(6)
Authors: Levy J.; Martin A.

Comparative study of pharmaceutical treatment of Peyronie’s disease
pp. 77-81(5)
Authors: Mavromanolakis E.; Sifakis G.; Nestoridis G.; Delakas D.; Maraki S.; Cranidis A.

Sexual dysfunction and sexual health concerns in women with diabetes
pp. 83-87(5)
Authors: Meeking D.R.; Fosbury J.A.; Cummings M.H.; Alexander W.D.; Shaw K.M.; Russell-Jones D.L.

Changes in ejaculatory latency and penile vibratory threshold with SS-cream in patients with primary premature ejaculation
pp. 89-93(5)
Authors: Xin Z.C.; Choi Y.D.; Lee W.H.; Chun D.C.; Choi H.K.; Kim D.K.

Apomorphine test: a beneficial clue for planning bromocriptine treatment in non-organic erectile dysfunction
pp. 95-97(3)
Authors: Pekirciolu L.; Karabulut A.; Özkarde H.; Germiyanolu C.; Erol D.

A randomized, double-blind, cross-over, placebo-controlled study of a novel topical lipid-based delivery system of prostaglandin E₁ in the treatment of erectile failure
pp. 99-104(6)
Authors: Foldvari M.; Wilson T.W.; Afridi S.K.; Kudel T.; Quest D.W.

Fluoxetine-related homosexual nightmares
pp. 105-105(1)
Authors: Michael A.; Berrios G.E.

Anorectal intercourse: an unusual cause of vaginal haematoma
pp. 107-108(2)
Authors: Khosla A.H.; Dahiya P.; Sangwan K.; Seth N.

Comment on, ‘Erectile-dysfunction clinic non-attendees’ by C. J. Larkin & W. W. Dinsmore
pp. 109-110(2)
Author: McDonnell G.V.

Erectile dysfunction alliance
pp. 110-111(2)
Author: Dinsmore W.W.

Reply to G. V. McDonnell
pp. 110-110(1)
Authors: Larkin C.J.; Dinsmore W.W.